Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Results from a major clinical trial demonstrate that both stenting and surgery are low-risk and similarly effective procedures for treating carotid artery disease.

" "

The results, published today in The Lancetwere announced simultaneously at the European Society of Cardiology Congress 2021.

Stroke is the second largest cause of death worldwide, responsible for over six million deaths each year. A common cause of stroke is carotid artery disease (also known as carotid artery stenosis), where the large blood vessels that supply oxygen to the brain become narrower. Usually, this is due to deposits of fatty material (atherosclerosis) in the arteries which eventually form hardened plaques.

To reduce their risk of having a deadly stroke, patients with carotid artery disease may undergo one of two different procedures to open up the affected artery and improve blood flow to the brain. Carotid artery surgery, also called carotid endarterectomy (CEA), involves surgically removing the plaque, and is more commonly prescribed. Alternatively, the artery may be opened by inserting a catheter with an inflatable balloon tip, and then a stent added to permanently keep the walls open (carotid artery stenting, CAS).

Up to now it has been unclear which of these procedures results in better overall patient outcomes. This includes both the long-term protective effect against strokes, and the risk of an adverse event happening during or immediately after the operation.

To generate robust evidence that could answer this, researchers have coordinated the Asymptomatic Carotid Surgery Trial 2 (ACST-2), the largest trial to date comparing CAS and CEA. The trial, hosted by the Nuffield Department of Population Health at the University of Oxford, enrolled 3,625 participants from 33 countries. Each participant had been diagnosed with carotid artery disease that had not caused  a stroke.

After agreeing to take part in the study, participants were randomly allocated to undergo either CAS or CEA, and followed up for an average of five years. The main outcomes assessed by the trial were adverse events associated with the procedure itself, and the long-term protective effect against strokes.

Key results:

  • There was no significant difference in the risk of adverse, procedure-related events for CAS and CEA. For both treatments, 1% of patients had a disabling stroke or died within 30 days (15 in the CAS group and 18 in the CEA group) and 2% had a non-disabling stroke (48 in the CAS group and 29 in the CEA group).
  • The number of strokes that occurred in the participants over the five-year follow up period was similar for CAS and CEA. Fatal or disabling stroke occurred in 2.5% of patients in each group, and the total number of strokes was 5.3% in the CAS group, and 4.5% in the CEA group.

Principal Investigator for ACST-2 Professor Alison Halliday, Professor of Vascular Surgery in the Nuffield Department of Surgical Sciences, University of Oxford, said: ‘We have shown that, for patients with a severely narrowed carotid artery, stenting and surgery have similar effects on the chances of having a disabling or fatal stroke. The risk from each procedure is about 1%. After that, however, the annual risk over the next five or more years is halved, from 1% down to 0.5% per year.’

Mr Richard Bulbulia, a Consultant Vascular Surgeon, Co-Principal Investigator for ACST-2, and Research Fellow at the Nuffield Department of Population Health, said: ‘Both stenting and surgery are good treatment options, but there may be particular patient factors which favour one approach over another. Until now, it had been unclear if CAS or CEA results in better overall outcomes on the risk of stroke. The evidence from this trial can give doctors confidence in offering the procedure most suited to their patients, knowing that both options are associated with similar very low risks.’

Similar stories

Society for Endocrinology 2022 Early Career Prize Lecture awarded to Catherine Lovegrove

We are delighted to share the fantastic news that Miss Catherine Lovegrove is one of two winners of the Society for Endocrinology (SfE) 2022 Early Career Prize Lecture.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Dimitrios Doultsinos wins Young Investigator Award from the Prostate Cancer Foundation

Dr Dimitrios Doultsinos, a John Black Research Fellow in Prostate Oncology at Oxford University's Nuffield Department of Surgical Sciences (NDS), was one of this year’s recipients of the highly coveted Prostate Cancer Foundation (PCF) Young Investigator Award.

Blog posts

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.